跳至主要内容
临床试验/CTRI/2023/12/060519
CTRI/2023/12/060519尚未招募3 期

A 24-week, multi-center, randomized, double-blind, placebo-controlled, three-armed, parallel design study to evaluate the efficacy and safety of Milk Basic Protein for height growth in children.

Ju Yeong NS Co. Ltd.2 个研究点 分布在 1 个国家目标入组 150 人开始时间: 2023年12月29日最近更新:

试验速览

阶段
3 期
状态
尚未招募
发起方
入组人数
150
试验地点
2
主要终点
Height (change in amount)

研究概览

简要总结

The aim of this clinical trial is to objectively demonstrate that Milk Basic Protein intake can support height growth in children, and based on the previous studies conducted Milk Basic Protein is expected to have a greater benefit than the risks including the side effects. The administration of nutritional interventions to undernourished children can promote catch-up growth more effectively in the very young. Therefore, efforts to prevent further growth faltering and promote catch-up growth should be given to children who have missed the growth.  Milk Basic Protein is a functional ingredient recognized to be may help to maintain healthy bone with in vitro studies showing increased osteoblast and chondrocyte proliferation, and animal studies showing increased bone mineral density and growth plate length. It is speculated that Milk Basic Protein can also help stimulate height growth in children. Individuals with a history of milk and dairy allergies should use caution when consuming the product. No prior clinical study has been conducted on the effect of Milk Basic Protein on children’s height growth.

研究设计

研究类型
Interventional
分配方式
Randomized
盲法
Participant, Investigator, Outcome Assessor and Date-entry Operator Blinded

入排标准

年龄范围
6.00 Year(s) 至 11.00 Year(s)(—)
性别
All

入选标准

  • 1.Children between the age of 6 and 11 years (both inclusive) at screening.
  • 2.Children within the range of 3rd percentile (inclusive of 3rd) and 50th percentile (exclusive of 50th) of height according to the Indian Academy of Pediatrics Growth Chart for the same gender and age.
  • 3.Children who did not develop secondary sexual characteristics according to investigator’s diagnosis (Tanner Stage1 only).
  • 4.School going children who voluntarily decide to participate after hearing a detailed explanation and fully understanding this study agree to abide the precautions by the written consent of both children their own and legal guardian.

排除标准

  • 1.Children who are sensitive or allergic to the investigational product. 2.Children who are being treated or have a history of chromosomal abnormalities, genetic abnormalities, skeletal dysplasia, achondroplasia/hypoplasia, etc. 3.Children with growth retardation due to endocrine diseases (growth hormone deficiency, hypothyroidism, type 1 diabetes, pituitary tumor, etc.) and chronic diseases. 4.Children who have been diagnosed with precocious puberty through the investigator’s medical examination, physical examination, and hormone test. 5.Children with bone age (months) differing from the chronological age by more than 18 months. 6.Children with severe anemia (6-11 years: children with hemoglobin less than 8 g/dL). 7.Children with weight less than 5th percentile of weight according to the Indian Academy of Pediatrics Growth Chart for the same gender and age. 8.Children with a history of intrauterine growth retardation (IUGR). 9.Children with birth weight less than 2.5 kg 10.Children who are diagnosed with or have a history of gastrointestinal disorders that may affect the absorption of the test food (e.g., gastrointestinal ulcer, gastritis, gastric spasm, gastroesophageal reflux disease, Chron’s disease) and gastrointestinal surgery (excluded for children with a history of appendectomy or hernia surgery). 11.Children who are being treated or have a corresponding disease with clinically significant liver, pancreas, kidney, nervous system, respiratory system, endocrine system, blood/tumor, mental disease, cardiovascular system, urinary system. Especially, children who have a history of serious heart disease, manic/hypomanic or bipolar disorder, major psychiatric disorders such as depression, anxiety disorder, suicidal tendency, and schizophrenia. 12.Children who took medicines, health functional food, or herb medicine related to height growth within 3 months prior to screening. 13.Children treated with hormone replacement therapy, calcitonin, phosphonate, or growth hormone within 6 months prior to screening. 14.Children who are diagnosed with ADHD or in treatment with drug (e.g., methylphenidate, etc.) within 3 months prior to screening. 15.Children who show any of the following results in clinical pathology tests.
  • AST or ALT 2.5 times greater than the upper limit of the normal range.
  • Serum Creatinine 2.5 times greater than the upper limit of the normal range. 16.Glycated hemoglobin (HbA1c) level greater than 6.5%. 17.Uncontrolled hypertension (systolic blood pressure greater than or equal to 130 mmHg, diastolic blood pressure greater than or equal to 80 mmHg) and heart rate greater than or equal to 140 bpm. 18.Children who participated in other clinical trials within 3 months prior to screening. 19.Children, judged by the principal investigator, who are inappropriate to participate in this study due to other reasons including diagnostic test results.

结局指标

主要结局

Height (change in amount)

时间窗: screening, baseline, week 8, week 16, and week 24

次要结局

  • 1 Height change in rate(2 Height Growth Velocity)
  • 1. Occurrence of Adverse Events(2. Weight and Body Mass Index)

研究者

发起方
Ju Yeong NS Co. Ltd.
申办方类型
Other [Miscellaneous Food Manufacturing]
责任方
Principal Investigator
主要研究者

Dr Abhishek Chavan

Noble care Childrens Hospital

研究点 (2)

Loading locations...

相似试验